Sorrento Therapeutics, Inc.’s abivertinib has shown positive results in two Phase II trials in hospitalized COVID-19 patients in the US and Brazil, according to preliminary data.
The oral capsule abivertinib could fill an unmet need for at-risk COVID-19 patients by significantly reducing progression to intubation, mechanical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?